(Lenvervimab)Biosimilar Reference Antibody-GS40371

货号：GS40371

Lenvervimab is a human monoclonal antibody developed as a prophylactic treatment against hepatitis B virus (HBV) infection. It specifically targets the hepatitis B surface antigen (HBsAg), which is present on the viral envelope and in excess as subviral particles in the bloodstream of infected individuals. By binding to HBsAg, lenvervimab aims to prevent the virus from entering hepatocytes, thereby blocking the initial establishment of infection or the spread of the virus within the liver. It is primarily investigated for use in preventing mother-to-child transmission (MTCT) of HBV when given to infants born to HBV-infected mothers, complementing the standard HBV vaccine and immunoglobulin regimen.